In that $35 PT, Barclays gives ABBV peak rev of $2.5b on v-pak. In the same report they say they now expect ex-US sales to account for 70% of global HCV sales up from their previous estimate of 45%. Something doesn't quite add up when you put those two #s together.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.